Search

everythinglearnresearchcommunity

for

Search:↓

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

Blocking IL-17 signaling may reduce skin inflammation and delay aging.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.

Blocking IL-17 signaling can delay skin aging and improve skin and hair health.

Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.

HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.

Granulomatous Alopecia Areata is rare and may be caused by hair antigens or follicle destruction.

Personalized treatment considering atopic status and cytokine profiles may help in managing pediatric alopecia areata.

The hydrogel patch helps heal diabetic wounds by releasing a healing agent in response to harmful molecules and improving skin regeneration.

Keratosis pilaris is often linked to genetic mutations and causes skin and hair abnormalities, regardless of those mutations.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Natural killer cells play a key role in autoimmune skin diseases like pemphigus vulgaris.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

Key genes linked to immune response are upregulated in hair follicles and skin tissues in chronic discoid lupus erythematosus.

Key genes linked to immune response are highly active in lupus-affected hair follicles.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Tph cells are linked to the severity of systemic lupus erythematosus.

STAT3 signaling is important for healthy skin and hair follicles, and its disruption can lead to skin conditions like atopic dermatitis.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

People with acne have more CD4+ immune cells in their skin than healthy people.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Non-ablative and ablative fractional lasers helped hair growth in some cases without major side effects, but didn't work for all hair disorders.

People with alopecia areata are more likely to have other immune-related conditions.